Gap-43 message levels in anterior cerebellum in Alzheimer's disease

Janet E. Cheetham, Mark R. Martzen, Ann Marie Kazee, Paul Coleman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We have previously reported that decreased growth-associated protein (GAP-43) message in frontal association cortex (area 9) of Alzheimer's disease (AD) patients is associated with increased density of neurons containing neurofibrillary tangles (NFTs). This finding leads to the hypothesis that decreased GAP-43 message in AD may be related to NFTs, rather than to some other aspect of AD pathology. Therefore, we predicted that in areas of brain unaffected by NFTs in AD the GAP-43 message levels should be similar to those of controls. The cerebellum is known to have a number of pathologies of AD, including diffuse plaques (DPs), microglial activation and reactive astrocytes. NFTs, however, are not typically found in the cerebellum mRNA was extracted from anterior cerebellum of AD and control cases, Northern- and slot-blotted and hybridized against a GAP-43 probe. Poly(dT) and glucose-3-phosphate dehydrogenase probes were used for normalization. The average relative GAP-43 message level was 0.582 in the AD cases and 0.448 in control cases. This 23% difference failed to reach statistical significance. Regression analysis within the AD group demonstrated that GAP-43 message level in cerebellar cortex was not significantly correlated with diffuse plaque density in cerebellar cortex. GAP-43 message levels in cerebellar cortex were also not correlated with summed density of neuritic plaques or summed density of NFTs in cortical regions - here used as an index of severity of disease. The data reported here also emphasize that the (NFT-dependent) reduction in GAP-43 mRNA levels previously reported in frontal association cortex in Alzheimer's disease appears to be region specific and not a general brain phenomenon. The preservation of normal GAP-43 message levels in the cerebellum in AD is consistent with the hypothesis that events related to NFT formation have a major impact on the expression of GAP-43 in Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)145-151
Number of pages7
JournalMolecular Brain Research
Volume36
Issue number1
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

GAP-43 Protein
Cerebellum
Neurofibrillary Tangles
Alzheimer Disease
Cerebellar Cortex
Frontal Lobe
Poly T
Pathology
Cerebellar Diseases
Messenger RNA
Amyloid Plaques
Brain
Astrocytes
Oxidoreductases
Phosphates
Regression Analysis

Keywords

  • Alzheimer's disease
  • Cerebellum
  • Diffuse plaque
  • GAP-43
  • mRNA levels
  • Neuritic plaque
  • Neurofibrillary tangle

ASJC Scopus subject areas

  • Molecular Biology
  • Cellular and Molecular Neuroscience

Cite this

Gap-43 message levels in anterior cerebellum in Alzheimer's disease. / Cheetham, Janet E.; Martzen, Mark R.; Kazee, Ann Marie; Coleman, Paul.

In: Molecular Brain Research, Vol. 36, No. 1, 01.01.1996, p. 145-151.

Research output: Contribution to journalArticle

Cheetham, Janet E. ; Martzen, Mark R. ; Kazee, Ann Marie ; Coleman, Paul. / Gap-43 message levels in anterior cerebellum in Alzheimer's disease. In: Molecular Brain Research. 1996 ; Vol. 36, No. 1. pp. 145-151.
@article{6b390fa90a0042b8981ea428f304d0d2,
title = "Gap-43 message levels in anterior cerebellum in Alzheimer's disease",
abstract = "We have previously reported that decreased growth-associated protein (GAP-43) message in frontal association cortex (area 9) of Alzheimer's disease (AD) patients is associated with increased density of neurons containing neurofibrillary tangles (NFTs). This finding leads to the hypothesis that decreased GAP-43 message in AD may be related to NFTs, rather than to some other aspect of AD pathology. Therefore, we predicted that in areas of brain unaffected by NFTs in AD the GAP-43 message levels should be similar to those of controls. The cerebellum is known to have a number of pathologies of AD, including diffuse plaques (DPs), microglial activation and reactive astrocytes. NFTs, however, are not typically found in the cerebellum mRNA was extracted from anterior cerebellum of AD and control cases, Northern- and slot-blotted and hybridized against a GAP-43 probe. Poly(dT) and glucose-3-phosphate dehydrogenase probes were used for normalization. The average relative GAP-43 message level was 0.582 in the AD cases and 0.448 in control cases. This 23{\%} difference failed to reach statistical significance. Regression analysis within the AD group demonstrated that GAP-43 message level in cerebellar cortex was not significantly correlated with diffuse plaque density in cerebellar cortex. GAP-43 message levels in cerebellar cortex were also not correlated with summed density of neuritic plaques or summed density of NFTs in cortical regions - here used as an index of severity of disease. The data reported here also emphasize that the (NFT-dependent) reduction in GAP-43 mRNA levels previously reported in frontal association cortex in Alzheimer's disease appears to be region specific and not a general brain phenomenon. The preservation of normal GAP-43 message levels in the cerebellum in AD is consistent with the hypothesis that events related to NFT formation have a major impact on the expression of GAP-43 in Alzheimer's disease.",
keywords = "Alzheimer's disease, Cerebellum, Diffuse plaque, GAP-43, mRNA levels, Neuritic plaque, Neurofibrillary tangle",
author = "Cheetham, {Janet E.} and Martzen, {Mark R.} and Kazee, {Ann Marie} and Paul Coleman",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/0169-328X(95)00257-S",
language = "English (US)",
volume = "36",
pages = "145--151",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Gap-43 message levels in anterior cerebellum in Alzheimer's disease

AU - Cheetham, Janet E.

AU - Martzen, Mark R.

AU - Kazee, Ann Marie

AU - Coleman, Paul

PY - 1996/1/1

Y1 - 1996/1/1

N2 - We have previously reported that decreased growth-associated protein (GAP-43) message in frontal association cortex (area 9) of Alzheimer's disease (AD) patients is associated with increased density of neurons containing neurofibrillary tangles (NFTs). This finding leads to the hypothesis that decreased GAP-43 message in AD may be related to NFTs, rather than to some other aspect of AD pathology. Therefore, we predicted that in areas of brain unaffected by NFTs in AD the GAP-43 message levels should be similar to those of controls. The cerebellum is known to have a number of pathologies of AD, including diffuse plaques (DPs), microglial activation and reactive astrocytes. NFTs, however, are not typically found in the cerebellum mRNA was extracted from anterior cerebellum of AD and control cases, Northern- and slot-blotted and hybridized against a GAP-43 probe. Poly(dT) and glucose-3-phosphate dehydrogenase probes were used for normalization. The average relative GAP-43 message level was 0.582 in the AD cases and 0.448 in control cases. This 23% difference failed to reach statistical significance. Regression analysis within the AD group demonstrated that GAP-43 message level in cerebellar cortex was not significantly correlated with diffuse plaque density in cerebellar cortex. GAP-43 message levels in cerebellar cortex were also not correlated with summed density of neuritic plaques or summed density of NFTs in cortical regions - here used as an index of severity of disease. The data reported here also emphasize that the (NFT-dependent) reduction in GAP-43 mRNA levels previously reported in frontal association cortex in Alzheimer's disease appears to be region specific and not a general brain phenomenon. The preservation of normal GAP-43 message levels in the cerebellum in AD is consistent with the hypothesis that events related to NFT formation have a major impact on the expression of GAP-43 in Alzheimer's disease.

AB - We have previously reported that decreased growth-associated protein (GAP-43) message in frontal association cortex (area 9) of Alzheimer's disease (AD) patients is associated with increased density of neurons containing neurofibrillary tangles (NFTs). This finding leads to the hypothesis that decreased GAP-43 message in AD may be related to NFTs, rather than to some other aspect of AD pathology. Therefore, we predicted that in areas of brain unaffected by NFTs in AD the GAP-43 message levels should be similar to those of controls. The cerebellum is known to have a number of pathologies of AD, including diffuse plaques (DPs), microglial activation and reactive astrocytes. NFTs, however, are not typically found in the cerebellum mRNA was extracted from anterior cerebellum of AD and control cases, Northern- and slot-blotted and hybridized against a GAP-43 probe. Poly(dT) and glucose-3-phosphate dehydrogenase probes were used for normalization. The average relative GAP-43 message level was 0.582 in the AD cases and 0.448 in control cases. This 23% difference failed to reach statistical significance. Regression analysis within the AD group demonstrated that GAP-43 message level in cerebellar cortex was not significantly correlated with diffuse plaque density in cerebellar cortex. GAP-43 message levels in cerebellar cortex were also not correlated with summed density of neuritic plaques or summed density of NFTs in cortical regions - here used as an index of severity of disease. The data reported here also emphasize that the (NFT-dependent) reduction in GAP-43 mRNA levels previously reported in frontal association cortex in Alzheimer's disease appears to be region specific and not a general brain phenomenon. The preservation of normal GAP-43 message levels in the cerebellum in AD is consistent with the hypothesis that events related to NFT formation have a major impact on the expression of GAP-43 in Alzheimer's disease.

KW - Alzheimer's disease

KW - Cerebellum

KW - Diffuse plaque

KW - GAP-43

KW - mRNA levels

KW - Neuritic plaque

KW - Neurofibrillary tangle

UR - http://www.scopus.com/inward/record.url?scp=0030046098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030046098&partnerID=8YFLogxK

U2 - 10.1016/0169-328X(95)00257-S

DO - 10.1016/0169-328X(95)00257-S

M3 - Article

C2 - 9011750

AN - SCOPUS:0030046098

VL - 36

SP - 145

EP - 151

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -